FY2029 Earnings Estimate for Pharvaris Issued By Wedbush

Pharvaris (NASDAQ:PHVS) – Equities researchers at Wedbush issued their FY2029 earnings estimates for shares of Pharvaris in a report issued on Monday, April 7th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of $5.99 for the year. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.06.

Separately, JMP Securities raised their target price on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Performance

PHVS stock opened at $11.83 on Wednesday. The business has a 50-day simple moving average of $15.98 and a two-hundred day simple moving average of $18.55. The company has a market capitalization of $618.59 million, a P/E ratio of -4.23 and a beta of -2.84. Pharvaris has a 52-week low of $11.76 and a 52-week high of $25.50.

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. Soleus Capital Management L.P. boosted its stake in shares of Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock worth $15,617,000 after buying an additional 216,483 shares during the last quarter. FMR LLC boosted its position in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company’s stock worth $103,429,000 after purchasing an additional 189,714 shares during the last quarter. Octagon Capital Advisors LP grew its stake in Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after purchasing an additional 157,530 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock valued at $8,510,000 after purchasing an additional 118,408 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Pharvaris by 483.9% during the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company’s stock worth $1,762,000 after purchasing an additional 76,188 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.